Global Antibody Drug Conjugate Market Outlook 2018 -




Published: March 2014 | Pages: 55 | Format: PDF

 The ADC technology is not new. It dates back to the 90s. However, several issues such as specificity of the payload (drug), and poor conjugation of drug and antibody proved a setback. But, the past few years have witnessed ADCs make a glorious comeback. This can be attributed to the significant advancements that have been made in the field of linker technology as well as payload efficacy and specificity. There are currently two ADC products in the market, Adcetris and Kadcyla. 

 According to our report, “Global Antibody Drug Conjugate Market Outlook 2018”, backed by improved understanding and better technology, the ADC market is anticipated to reach US$ 3.45 Billion by 2018. Our report analyzes the market for Adcetris and Kadcyla in detail. Market potential for these drugs has been estimated keeping in mind the fact that these drugs are being tested in clinical trials for various indications apart from the ones for which they are approved. These drugs will take some time in order to capture their entire potential market. 

 The report also provides an insight into the key ADCs that are currently in pipeline. At present, only one drug, Inotuzumab Ozogamicin is in late stage clinical trial. Apart from new drug candidates, previously approved drugs are also in late stage trials for other indications. Later in the report, strategic activities such as mergers, acquisitions and collaborations that have taken place over ADC have been provided. These activities are aimed at combining technologies and capabilities of other companies with inherent ones for the development of ADCs. 

 Major drivers such as advances in linker technology and patent fencing through ADC development have been discussed. In an attempt to protect their innovative blockbuster drugs, many pharma giants are moving towards ADCs. These moves are going to have a major impact in shaping the ADC market in the coming years. On the other hand, challenges such as the high cost of production of ADCs; difficult upstream and downstream processing; safety considerations etc., will have to be taken care of. 

 At the end, major players of the ADC market have been discussed. A brief business overview of every player has been provided along with their product and pipeline portfolio and recent developments. A comparative strength and weakness analysis of these players has also been done. Whereas on one hand, a player is experienced owing to previously approved ADC, on the other it has licensed ADC technology from top providers. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors. 

 1. Analyst View 

 2. Research Methodology 

 3. Antibody Drug Conjugate (ADC) - An Introduction 

 4. ADC Market Outlook to 2018 

 4.1 Adcetris 

 4.1.1 Market Potential 

 4.1.2 Market Size and Forecasts to 2018 

 4.2 Kadcyla 

 4.2.1 Market Potential 

 4.2.2 Market Size and Forecasts to 2018 

 5. Current Status and Potential of Key ADC in Pipeline 

 5.1 Inotuzumab Ozogamicin/CMC-544 - Pfizer 

 5.2 Glembatumumab Vedotin/CDX-011 - Celldex Therapeutics 

 5.3 SAR-3419 - Sanofi 

 5.4 PSMA-ADC - Progenics Pharmaceuticals 

 5.5 RG-7596 - Roche 

 5.6 RG-7593 - Roche 

 6. Strategic Collaborations in the ADC Industry 

 7. Drivers and Challenges 

 8. Competitive Landscape 

 8.1 Roche 

 8.2 Sanofi 

 8.3 Progenics 

 8.4 Seattle Genetics 

 8.5 Celldex Therapeutics 

  

 List of Figures 

 Figure 3 1: ADC - Mechanism of Action 

 Figure 4 1: Global - ADC Market (Million US$), 2013 & 2018 

 Figure 4 2: Global - Adcetris Market (Million US$), 2011 & 2012 

 Figure 4 3: Global - Adcetris Market (Million US$), 2013 & 2018 

 Figure 4 4: Global - Kadcyla Market (Million US$), 2013 & 2018 

  

 List of Tables 

 Table 4 1: Potential Patients for Adcetris (2012) 

 Table 4 2: Ongoing Trials for Adcetris 

 Table 4 3: Potential Patients for Kadcyla (2012) 

 Table 4 4: Ongoing Trials for Kadcyla 

 Table 5 1: ADCs in Pipeline 

 Table 6 1: Strategic Collaborations in the ADC Industry 

 Table 8 1: Roche - ADCs in Pipeline 

 Table 8 2: Roche - Strengths and Weaknesses 

 Table 8 3: Sanofi - ADCs in Pipeline 

 Table 8 4: Sanofi - Strengths and Weaknesses 

 Table 8 5: Progenics - ADCs in Pipeline 

 Table 8 6: Progenics - Strengths and Weaknesses 

 Table 8 7: Seattle - ADCs in Pipeline 

 Table 8 8: Seattle Genetics - ADC Collaborator Pipeline 

 Table 8 9: Seattle - Strengths and Weaknesses 

 Table 8 10: Celldex Therapeutics - ADC Pipeline 

 Table 8 11: Celldex Therapeutics - Strengths and Weaknesses